Ascentage Pharma Group (AAPG) said late Tuesday it has received an investigational new drug clearance from the US Food and Drug Administration for oncology drug candidate APG-3288.
The company plans to advance the drug into a phase 1 trial in patients with relapsed/refractory B-cell malignancies.